eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2017
vol. 68
 
Share:
Share:
more
 
 
abstract:
Original paper

The significance of angiogenesis for predicting optimal therapeutic response in chronic myeloid leukaemia patients

Irena Ćojbašić, Lana Mačukanović-Golubović, Dragan Mihailović, Miodrag Vučić, Žarko Ćojbašić

Pol J Pathol 2017; 68 (3): 241-251
Online publish date: 2017/11/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
In this study the correlation and the prognostic value of the morphometric parameters of angiogenesis for optimal therapeutic response to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukaemia (CML), i.e. complete cytogenetic response (CCgR) and major molecular response (MMoR), were investigated. Microvascular density (MVD) and a number of different size- and shape-related morphometric parameters of microvessels of bone marrow biopsy from 40 CML patients and 20 controls were examined. Microvessels of bone marrow were examined by using immunohistochemical staining for CD34 and quantified in the region of the most intense vascularisation by using image analysis.

CML patients had significantly higher angiogenesis parameters when compared with controls. A statistically significant correlation was found between some parameters of angiogenesis and evaluated CCgR and MMoR. For achievement of CCgR, lower values of MVD, minor axis, area, circularity, and roundness and higher value of aspect ratio, while for achievement of MMoR only lower values of MVD have been identified as positive prognostic factors.

Besides confirming increased angiogenesis in CML patients, this study also demonstrated prognostic significance of the degree of angiogenesis for the clinical outcome and identified angiogenic predictive factors for achieving optimal response on TKIs therapy.
keywords:

chronic myeloid leukaemia, angiogenesis, microvessel morphometry, prognosis, outcome

references:
Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 2004; 28 Suppl 1: S21-28.
Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A: 2534-2539.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
Aguayo A, O’Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 768-770.
Padró T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
Hussong JW, Rodgers JM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-313.
Korkolopoulou P, Apostolidou E, Pavlopoulos PM, et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 2001; 15: 1369-1376.
Lundberg LG, Hellstrom-Lindberg E, Kanter-Lewensohn L, et al. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res 2006; 30: 247-253.
Savić A, Čemerikić-Martinović V, Dovat S, et al. Angiogenesis and survival in patients with myelodysplastic syndrome. Pathol Oncol Res 2012; 18: 681-690.
Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-3116.
Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
Lundberg LG, Lerner R, Sundelin P, et al. Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol 2000; 157: 15-19.
Di Raimondo F, Palumbo GA, Molica S, et al. Angiogenesis in chronic myeloproliferative diseases. Acta Haematol 2001; 106: 177-183.
Hochhaus A, O’Brien SG, Guilhot F, et al. Six year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
Jabbour E, Kantarjian H, O’Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011; 118: 4541-4546.
Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353-1360.
Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 2004; 103: 3549-3551.
Korkolopoulou P, Viniou N, Kavantzas N, et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 2003; 17: 89-97.
Ebos JM, Tran J, Master Z, et al. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res 2002; 1: 89-95.
Baccarani M, Cortes J, Pane FD, et al. Chronic myeloid leukemia. An update of concepts and management Recommendations of the European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884.
Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
Hsu SM, Raine L, Fanger L. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparasion between ABC and unlabelled antibody (PAP) procedures. J Hisohem Cytochem 1981; 29: 577-580.
Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
Vermeulan PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumorous; an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32: 2474-2484.
Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
Janowska-Wieczorek A, Majka M, Marquez-Curtis L, et al: Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Martigel implants. Leukemia 2002; 16: 1160-1166.
Gunsilius E, Duba HC, Petzer AL, et al. Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000; 355: 1688-1691.
Green AR. Hemangioblast origin of chronic myeloid leukaemia? Lancet 2000; 355:1659-1660.
Buchdunger E, O’Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38 (suppl 5): S28-S36.
Michalak SS, Gil L. Patient with chronic myeloid leukemia – challenge for primary care physician. Fam Med Prim Care Rev 2015; 17: 43-47.
Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 2004; 104: 495-501.
Holtz MS, Slovak ML, Zhang F, et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800.
Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002; 99: 381-383.
Simsek ET, Eskazan AE, Cengiz M, et al. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukemia. J Clin Pathol 2016; 69: 810-816.
Eliacik E, Isik A, Aydin C, et al. Bone marrow fibrosis may be an effective independent predictor of the TKI drug response level in chronic myeloid leukemia. Hematology 2015; 20: 392-396.
Dolgikh TY, Dominikova NP, Tornuev YV, et al. Incidence of myelofibrosis in chronic myeloid leukemia, multiple myeloma and chronic lymphoid leukemia during various phases of diseases. Bull Exp Biol Med 2017; 162: 483-487.
Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of the tyrosine kinase inhibitor Imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia. Histol Histopathol 2004; 19: 1277-1288.
Rumpel M, Friedrich T, Deininger MW. Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 4641-4643.
Ćojbašić I, Mačukanović-Golubović L, Mihailović D, et al. Improved prediction of clinical outcome in chronic myeloid leukemia. Int J Hematol 2015; 101: 173-183.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe